The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•5 June 2026•

2 min read

Alvotech Shares Surge 19% on FDA Resubmissions for Key Biosimilars

Key Facts

1Alvotech resubmitted Biologics License Applications (BLAs) for its biosimilar candidates AVT05 and AVT06 to the US FDA.

2The FDA review for the resubmitted applications is expected to be completed within six months.

In a move reflecting the accelerating pace of regulatory milestones in the biotech sector, Alvotech shares surged 19% following the company's announcement of significant progress in its regulatory pathway. According to reports, the company resubmitted Biologics License Applications (BLAs) for its biosimilar candidates AVT05 and AVT06 to the US Food and Drug Administration (FDA). The FDA review for these resubmitted applications is expected to be completed within approximately six months, moving the firm closer to potential commercialization in the US market.

This sharp rally comes as the biotech sector faces intense competition, with Alvotech striving to capture market share from peers like Amgen and Sandoz, the latter of which recently reported a 6% growth in biosimilar sales for the last quarter per market data. The resubmission is viewed as a positive signal that previous regulatory hurdles have been addressed, leading analysts at Zacks to improve their outlook based on the increased probability of near-term approvals.

Investors should monitor the review progress throughout the second half of the year, as the final FDA decision remains the primary catalyst for the stock's next move. Looking at the economic calendar, traders are awaiting Fed Chair Powell's speech on May 31, 2026, which could impact risk appetite across growth and biotech sectors. Liquidity levels and price volatility will remain under scrutiny as the deadline for the technical review results approaches.